ClinicalTrials.gg
CompletedNCT05384262Updated Sep 9, 2026

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

A Phase 1 interventional study of AZD0780 and AZD0780 in Dyslipidemia, sponsored by AstraZeneca. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing laroprovstat in Dyslipidemias — none open to participants now, 1 under way, 1 of them phase 3. laroprovstat · Dyslipidemias.

Enrollment
3rd of 11
183 · median 59
Started
2022
the only one that year
Phase 1
8 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
11 of 11
AstraZeneca

Among the 11 studies testing laroprovstat in Dyslipidemias, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 8 in phase 1, and was the 1st registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

None of the 11 studies testing laroprovstat in Dyslipidemias is open now. The open studies under Dyslipidemias, anywhere →

About laroprovstat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing laroprovstat in Dyslipidemias as a file.
02

Study summary

This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD0780 following single and multiple dose administration to healthy subjects with or without elevated Low-Density Lipoprotein-Cholesterol (LDL-C) levels.

This study will consist of two parts (Parts A and B).

56 subjects have been planned for Part A and 141 subjects for Part B. Additional subjects may be included for the optional cohorts depending upon emerging data.

Read the detailed description

This is a Phase I, First In Human (FIH), randomized, single-blind, placebo-controlled, study in healthy male and/or female subjects of non-childbearing potential including healthy subjects of Chinese and Japanese ethnicity performed at multiple centers (up to 4 study centers).

56 subjects have been planned for Part A and 141 subjects for Part B.

  • Part A:

    • A Screening Period of maximum 28 days.
    • Admission to study center (Day -1 or Day -2).
    • A Treatment Period (Day 1 to Day 3) with a single dose of AZD0780 or placebo on Day 1. Subjects will be discharged on Day 3.
    • A Follow-up Visit within 5 to 7 days after the Investigational Medicinal Product (IMP) dose for all cohorts.
    • An additional Follow-up Visit within 9 to 11 days after the IMP dose from Cohort 3 onwards.

      (i) Part A1 - Up to 5 dose cohorts of AZD0780 are planned to be investigated. Depending on the findings, up to 4 additional dose cohorts may be added. Within each cohort, 6 subjects will be randomized to receive AZD0780, and 2 subjects randomized to receive placebo. Dosing for each ascending dose cohort will proceed with 2 subjects in a sentinel sub-cohort such that one subject will be randomized to receive AZD0780, and one subject will be randomized to receive placebo.

(ii) Part A2 - The subjects from a chosen cohort in Part A1 will return to the study center no sooner than 9 days after the first dose administration of IMP and will receive AZD0780 or placebo after intake of a high-calorie, high-fat breakfast, to assess the effect of food on the PK of AZD0780.

The subjects will stay at the study center until 48 hours post-dose in both the parts.

  • Part B:
  • Global Multiple Ascending Dose (MAD) cohort - Up to 3 dose cohorts are planned to be investigated. In each cohort, 20 subjects will participate and receive either AZD0780 or placebo, randomized 3:1 for 28 days dosing. Depending on the findings, 3 additional dose levels may be added in up to 3 additional cohorts (up to 20 subjects per cohort).
  • Japanese Single and Multiple Ascending Dose (JSMAD) cohorts - Two cohorts are planned. One cohort of 8 Japanese subjects will receive a medium dose level of AZD0780 or placebo randomized 3:1 for 9 days dosing (subjects will receive a single dose of IMP on Day 1 followed by daily dosing on Days 8 to 15 [there is no dose on Days 2 to 7]). The second cohort of 8 Japanese subjects will receive a higher dose level of AZD0780 or placebo.
  • Rosuvastatin global MAD cohorts - Two cohorts are planned. Up to 40 subjects in the first cohort will receive either AZD0780 in combination with rosuvastatin or placebo in combination with rosuvastatin, randomized 1:1 to 1 of the 2 treatment arms with 20 subjects per arm. Up to 25 subjects will participate in the second cohort and will be randomized 4:1 to 1 of 2 treatment arms to receive either AZD0780 in combination with rosuvastatin (20 subjects) or placebo in combination with rosuvastatin (5 subjects). Subjects eligible for these cohorts will begin a Screening period of 56 days, a minimum of 21 days run-in period (maximum of up to 28 days), Treatment period of 28 days for each cohort and two Follow-up visits (1 \& 2 weeks after last dose of IMP).
03

Conditions studied

  • Dyslipidemia

Keywords

  • Elevated LDL-C
  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures (including the Pre Screening Visit for Part B).
  • Healthy male and female subjects (of nonchildbearing potential), aged 18 to 55 years inclusive, with suitable veins for cannulation or repeated venipuncture.
  • Females must have a negative pregnancy test at the Screening Visit and on admission to the study center, must not be lactating and must be of non , confirmed at the Screening Visit by fulfilling one of the following criteria:

    1. defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range.
    2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  • Have a between 18 and 35 kg/m2 inclusive and weigh at least 50 kg and no more than 120 kg inclusive at the Screening Visit and on admission to the study center.
  • For Japanese subjects (Part B) and Chinese subjects (Part A):

    1. A subject will be considered Japanese if both parents and all grandparents are Japanese, the subject was born in Japan, and the subject has not lived outside Japan for more than 10 years.
    2. A subject will be considered Chinese if both parents and all grandparents are Chinese, the subject was born in China, and the subject has not lived outside China for more than 10 years.
  • For Part B (MAD), at the Screening Visit subjects must have LDL-C ≥ 70 mg/dL but ≤ 190 mg/dL (or ≥ 1.8 mmol/L but ≤ 4.9 mmol/L for London EPCU [Early Phase Clinical Unit]), and triglycerides \< 400 mg/dL (or \< 10.3 mmol/L for London EPCU).
  • For Part B (rosuvastatin global MAD), at the Screening Visit subjects must have LDL-C ≥ 100 mg/dL but \< 190 mg/dL (≥ 2.6 mmol/L but ≤ 4.9 mmol/L for London EPCU).

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder.
  • History or presence of gastrointestinal, hepatic or, renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first vaccination within 30 days prior to randomization.
  • SARS-CoV-2 second vaccination within 10 days of screening.
  • Confirmed Coronavirus disease 2019 (COVID-19) infection during screening and admission, by Polymerase Chain Reaction (PCR) test (in the London EPCU, COVID-19 infection before or during Screening and/or admission will be confirmed by a COVID-19 test. Subjects will undergo COVID-19 testing prior to ICF signing and any subject testing positive will not be screened for the study).
  • Any clinically important abnormalities in clinical chemistry, coagulation, hematology, or urinalysis results.
  • Any positive result on Screening for serum surface antigen, antibody, and (HIV).
  • Abnormal vital signs after 10 minutes supine rest at the Screening Visit and on admission to the study center.
  • Any clinically important abnormalities in rhythm, conduction or morphology of the resting (ECG) and any clinically important abnormalities in the 12-lead ECG that may interfere with the interpretation of ECG interval measured from the onset of the QRS complex to the end of the T wave () corrected for heart rate (QTc) interval changes including abnormal ST-T-wave morphology at the Screening Visit and/or on admission to the study center.
  • Known or suspected history of drug abuse.
  • Current smokers or those who have smoked or used nicotine products within the previous 3 months.
  • History of alcohol abuse or excessive intake of alcohol.
  • Positive screen for drugs of abuse, cotinine (nicotine), or alcohol at Screening and/or admission to the study center.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0780.
  • Excessive intake of caffeine-containing drinks or food.
  • Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.
  • Use of any prescribed or nonprescribed medication including antacids, analgesics, herbal remedies, mega-dose vitamins, and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half-life.
  • Plasma donation within one month of the Screening Visit or any blood donation/blood loss during the 3 months prior to the Screening Visit.
  • Has received another new chemical entity within 30 days or 5 half-lives of the first administration of IMP in this study.
  • Subjects who have previously received AZD0780 within 60 days of the first administration of IMP in this study.
  • Involvement of any Astra Zeneca or study center employee or their close relatives.
  • Any ongoing or recent minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
  • Subjects who are vegans or have medical dietary restrictions.
  • Subjects who cannot communicate reliably with the investigator.
  • Vulnerable subjects.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
183 participants (actual)

Study arms

  • Active comparator
    Cohort 1: Part A1 - AZD0780 dose 1/placebo tablet

    A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 2: Part A1 - AZD0780 dose 2/placebo tablet

    A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 3: Part A1 - AZD0780 dose 3/placebo tablet

    A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 4: Part A1 - AZD0780 dose 4/placebo tablet

    A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 5: Part A1 - AZD0780 dose 5/placebo tablet

    A total of 6 subjects will receive single ascending doses of AZD0780 and 2 will receive placebo.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 6: Part B - AZD0780 dose 6/placebo tablet

    A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 7: Part B - AZD0780 dose 7/placebo tablet

    A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 8: Part B - AZD0780 dose 8/placebo tablet

    A total of 20 subjects will be assigned as 3:1::AZD0780:Placebo to receive multiple ascending doses.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 9: Part B - AZD0780 dose 9/placebo tablet

    A total of 6 subjects will receive single and multiple ascending doses of AZD0780 and 2 will receive placebo.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 10: Part B - AZD0780 dose 10/placebo tablet

    A total of 6 subjects will receive single and multiple ascending doses of AZD0780 and 2 will receive placebo.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 11: Part A2 - AZD0780 dose 11/placebo tablet

    A total of 5 subjects will receive single ascending doses of AZD0780 and placebo.

    Drug: AZD0780 · Drug: Placebo

  • Active comparator
    Cohort 12: Part B - AZD0780 dose 1/rosuvastatin dose 12

    A total of 20 subjects will receive single dose of AZD0780 and rosuvastatin.

    Drug: AZD0780 · Drug: Rosuvastatin

  • Active comparator
    Cohort 13: Part B - placebo tablet/rosuvastatin dose 12

    A total of 20 subjects will receive single dose of placebo and rosuvastatin.

    Drug: Placebo · Drug: Rosuvastatin

  • Active comparator
    Cohort 14: Part B - AZD0780 with placebo tablet/AZD0780 with rosuvastatin dose 12

    A total of 20 subjects will receive AZD0780 in combination with rosuvastatin or 5 subjects will receive placebo in combination with rosuvastatin.

    Drug: AZD0780 · Drug: Placebo · Drug: Rosuvastatin

Interventions

  • Subjects will receive AZD0780 orally as a single ascending dose.

  • Subjects will receive AZD0780 orally as a multiple ascending dose.

  • Subjects will receive AZD0780 orally as a single and multiple ascending dose.

  • DrugPlacebo

    Subjects will receive placebo matching the AZD0780 dose orally as a single ascending dose.

  • DrugPlacebo

    Subjects will receive placebo matching the AZD0780 dose orally as a multiple ascending dose.

  • DrugPlacebo

    Subjects will receive placebo matching the AZD0780 dose orally as a single and multiple ascending dose.

  • Subjects will receive rosuvastatin orally.

06

What researchers measure

Primary outcomes

  1. Number of subjects with Adverse Events

    The safety and tolerability of AZD0780 following oral administration of single ascending doses (Part A) and multiple ascending doses (Part B) will be assessed.

    Time frame: From Screening (≤ 28 days) until Follow-up Visit (5 to 7 days post-dose for all cohorts, and 9 to 11 days post-dose for subjects from Cohort 3 onwards)

Secondary outcomes

  1. Area under plasma concentration time curve from zero to infinity (AUCinf)

    The single dose and steady state AUCinf of AZD0780 following oral administration of AZD0780 will be assessed.

    Time frame: SAD cohorts: Day 1-3 until 5-7 days (cohort 1 & 2) & 9-11 days (cohort 3 onwards) post-dose; JSMAD cohorts: Day 1-3,5,8,10,13,15,16 until 7-10 days post-dose; MAD Cohorts: Day 1 to 3,5,8,9,12,15,18,22,25,29 until Days 36, 43 [± 1day]

  2. Area under plasma concentration time curve from zero to t hours post-dose (AUC[0-t])

    The single dose and steady state AUC(0-t) of AZD0780 following oral administration of AZD0780 will be assessed.

    Time frame: SAD cohorts: Day 1-3 until 5-7 days (cohort 1 & 2) & 9-11 days (cohort 3 onwards) post-dose; JSMAD cohorts: Day 1-3,5,8,10,13,15,16 until 7-10 days post-dose; MAD Cohorts: Day 1 to 3,5,8,9,12,15,18,22,25,29 until Days 36, 43 [± 1day]

  3. Area under the plasma concentration-curve across the dosing interval (AUCτ)

    The single dose and steady state AUCτ of AZD0780 following oral administration of AZD0780 will be assessed.

    Time frame: SAD cohorts: Day 1-3 until 5-7 days (cohort 1 & 2) & 9-11 days (cohort 3 onwards) post-dose; JSMAD cohorts: Day 1-3,5,8,10,13,15,16 until 7-10 days post-dose; MAD Cohorts: Day 1 to 3,5,8,9,12,15,18,22,25,29 until Days 36, 43 [± 1day]

  4. Maximum observed plasma (peak) drug concentration [Cmax]

    The single dose and steady state Cmax of AZD0780 following oral administration of AZD0780 will be assessed.

    Time frame: SAD cohorts: Day 1-3 until 5-7 days (cohort 1 & 2) & 9-11 days (cohort 3 onwards) post-dose; JSMAD cohorts: Day 1-3,5,8,10,13,15,16 until 7-10 days post-dose; MAD Cohorts: Day 1 to 3,5,8,9,12,15,18,22,25,29 until Days 36, 43 [± 1day]

  5. Amount of unchanged drug excreted into urine from zero to the last quantifiable concentration by interval and cumulatively (Ae[0-last])

    The single dose and steady state Ae\[0-last\] of AZD0780 following oral administration of AZD0780 will be assessed.

    Time frame: SAD cohorts (Parts A1 & A2): Day 1 to Day 3; JSMAD cohorts (Part B): Day 1 & 15; Global MAD Cohorts Day 1 & 10; Rosuvastatin Global MAD Cohorts (Part B): Day 1 & 8

  6. Percentage of dose excreted unchanged in urine from zero to the last quantifiable concentration, by interval and cumulatively (fe[0-last])

    The single dose and steady state fe\[0-last\] of AZD0780 following oral administration of AZD0780 will be assessed.

    Time frame: SAD cohorts (Parts A1 & A2): Day 1 to Day 3; JSMAD cohorts (Part B): Day 1 & 15; Global MAD Cohorts Day 1 & 10; Rosuvastatin Global MAD Cohorts (Part B): Day 1 & 8

  7. Renal clearance of drug from plasma (CLR)

    The single dose and steady state CLR of AZD0780 following oral administration of AZD0780 will be assessed.

    Time frame: SAD cohorts (Parts A1 & A2): Day 1 to Day 3; JSMAD cohorts (Part B): Day 1 & 15; Global MAD Cohorts Day 1 & 10; Rosuvastatin Global MAD Cohorts (Part B): Day 1 & 8

  8. LDL-C

    The pharmacodynamics (PD) of AZD0780 by assessment of LDL-C following oral administration of single ascending doses (Part A) and multiple ascending doses (Part B) will be assessed.

    Time frame: LDL-C SAD cohorts: Days 1,2,3,5-7,9-11 LDL-C JSMAD cohorts: Days 1,2,3,10,15,16,17;LDL-C Global MAD Cohorts: Days 1,2,3,5,8,12,22, 25,29,36-43;LDL-C Rosuvastatin Global MAD Cohorts:Days -28,-8,-1,1,2,3,5,8,12,15,18,22,29,36-43

  9. Proprotein convertase subtilisin/kexin type 9 (PCSK9)

    The PD of AZD0780 by assessment of total PCSK9 (and compound stabilized PCSK9 for Part A) following oral administration of single ascending doses (Part A) will be assessed.

    Time frame: PCSK9 SAD cohorts: Days 1,2,3;PCSK9 JSMAD cohorts:Days 1,2,3,10,15,16,17,22-25;PCSK9 Global MAD Cohorts:Days 1,8,15,22,29,36-43; PCSK9 Rosuvastatin Global MAD Cohorts:Days 1,8,15,22,29,36-43

07

Study locations

3 sites
  • Research Site
    Glendale, California 91206, United States
  • Research Site
    Brooklyn, Maryland 21225, United States
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
08

References and documents

Publications

  • Vega RB, O'Mahony G, Barbour AM, Yu H, Knochel J, Brengdahl J, Hochdorfer T, Bergenholm L, Toppner Carlsson E, Ahnmark A, Underwood CR, Rudvik A, Carter D, Laru J, Gutgsell A, Twaddle L, Garkaviy P, Bogstedt A, Hurt-Camejo E, Miliotis T, Ryaboshapkina M, Hober A, Hubbard B, Serrano-Wu M, Kaushik V, Geschwindner S, McCarthy MC, Linden D, Rosenmeier JB. Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients. Circulation. 2026 Jun 23;153(25):1999-2010. doi: 10.1161/CIRCULATIONAHA.125.075973. Epub 2026 May 15. PubMed 42137960 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2024, 24 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 24 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2022
First posted
May 20, 2022
StartActual
May 18, 2022
Primary completionActual
Jun 14, 2024
CompletionActual
Jun 14, 2024
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05384262
Lead sponsor
AstraZeneca
Collaborators
Parexel
Responsible party
Sponsor
First posted
May 20, 2022
Start date
May 18, 2022
Primary completion
Jun 14, 2024
Completion
Jun 14, 2024
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Laroprovstat · Rosuvastatin

Start the discussion